Vincent A, et al. - Researchers investigated the specific targets of voltage-gated potassium channel–complex antibodies that are found in acquired neuromyotonia, and assessed if these antibodies are associated with additional clinical features of tumors, pain, or autonomic or central disorders. Outcomes of this cohort study of 38 patients with electrophysiologically-confirmed neuromyotonia (NMT), reviewed clinically between February 2007 and August 2009, in the Universities of Sydney and Kagoshima and followed up across 2 to 4 years, in combination with a patient-led survey indicate that 45% of patients with neuromyotonia variably exhibit antibodies to the extracellular aspects of leucine-rich glioma inactivated protein, contactin-associated protein 2, and contactin 2. Antibodies to voltage-gated potassium channel–complex proteins individually do not relate to specific clinical features, but the type and severity of pain were found to exert a substantial influence on the quality of life that need greater recognition.